MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
Oncotarget
; 13: 1217-1236, 2022 Nov 02.
Article
in En
| MEDLINE
| ID: mdl-36342456
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Protein Kinase Inhibitors
/
STAT Transcription Factors
/
Cyclin-Dependent Kinase 8
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Oncotarget
Year:
2022
Document type:
Article
Affiliation country: